| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms, Castration-Resistant | 32 | 2024 | 111 | 8.680 |
Why?
|
| Prostatic Neoplasms | 25 | 2023 | 1721 | 2.980 |
Why?
|
| Androstenes | 12 | 2024 | 43 | 2.880 |
Why?
|
| Phenylthiohydantoin | 18 | 2024 | 41 | 2.790 |
Why?
|
| Benzamides | 18 | 2024 | 229 | 2.270 |
Why?
|
| Receptors, Androgen | 13 | 2024 | 113 | 2.040 |
Why?
|
| Nitriles | 18 | 2024 | 149 | 2.010 |
Why?
|
| Receptors, Glucocorticoid | 6 | 2024 | 120 | 1.840 |
Why?
|
| Neoplastic Cells, Circulating | 6 | 2024 | 70 | 1.380 |
Why?
|
| Antineoplastic Agents | 11 | 2023 | 2360 | 1.200 |
Why?
|
| Androgen Antagonists | 11 | 2023 | 144 | 1.170 |
Why?
|
| Neoplasm Metastasis | 18 | 2021 | 1056 | 1.110 |
Why?
|
| Sulfonamides | 5 | 2019 | 300 | 0.930 |
Why?
|
| Food-Drug Interactions | 2 | 2014 | 18 | 0.920 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 9 | 2022 | 2438 | 0.920 |
Why?
|
| Male | 59 | 2024 | 40965 | 0.850 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 589 | 0.800 |
Why?
|
| Androgen Receptor Antagonists | 5 | 2023 | 18 | 0.800 |
Why?
|
| Testosterone | 4 | 2021 | 271 | 0.720 |
Why?
|
| Antineoplastic Agents, Immunological | 2 | 2019 | 185 | 0.690 |
Why?
|
| Orchiectomy | 4 | 2018 | 68 | 0.680 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2024 | 383 | 0.660 |
Why?
|
| Ascites | 1 | 2018 | 55 | 0.630 |
Why?
|
| Pyrimidines | 5 | 2019 | 370 | 0.620 |
Why?
|
| Humans | 66 | 2024 | 86643 | 0.620 |
Why?
|
| Food | 1 | 2018 | 86 | 0.610 |
Why?
|
| Prospective Studies | 12 | 2024 | 4213 | 0.600 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2023 | 302 | 0.600 |
Why?
|
| Prostate-Specific Antigen | 7 | 2022 | 353 | 0.590 |
Why?
|
| Gene Expression Regulation, Neoplastic | 5 | 2018 | 1197 | 0.580 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 61 | 0.580 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 159 | 0.580 |
Why?
|
| Aged, 80 and over | 22 | 2021 | 6509 | 0.570 |
Why?
|
| Quality of Life | 5 | 2022 | 1585 | 0.560 |
Why?
|
| SOXB1 Transcription Factors | 3 | 2023 | 21 | 0.550 |
Why?
|
| Aged | 33 | 2024 | 18415 | 0.540 |
Why?
|
| Cell Line, Tumor | 9 | 2024 | 2426 | 0.530 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2016 | 592 | 0.500 |
Why?
|
| Prednisone | 4 | 2022 | 258 | 0.490 |
Why?
|
| Disease Progression | 7 | 2020 | 1531 | 0.490 |
Why?
|
| Patient Safety | 4 | 2019 | 212 | 0.480 |
Why?
|
| Immediate-Early Proteins | 2 | 2014 | 164 | 0.470 |
Why?
|
| Carcinoma, Small Cell | 1 | 2014 | 134 | 0.470 |
Why?
|
| MAP Kinase Kinase 4 | 2 | 2011 | 67 | 0.470 |
Why?
|
| Middle Aged | 29 | 2021 | 25028 | 0.460 |
Why?
|
| Dietary Fats | 1 | 2014 | 135 | 0.460 |
Why?
|
| Food Labeling | 1 | 2012 | 8 | 0.450 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2018 | 930 | 0.430 |
Why?
|
| Indoles | 1 | 2014 | 318 | 0.420 |
Why?
|
| Neoplasms | 6 | 2023 | 2898 | 0.420 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2011 | 63 | 0.390 |
Why?
|
| Melanoma | 1 | 2014 | 459 | 0.360 |
Why?
|
| Signal Transduction | 9 | 2024 | 3241 | 0.350 |
Why?
|
| Mice, Nude | 4 | 2017 | 790 | 0.350 |
Why?
|
| Cell Survival | 3 | 2017 | 969 | 0.340 |
Why?
|
| Mifepristone | 2 | 2022 | 33 | 0.330 |
Why?
|
| Treatment Outcome | 15 | 2023 | 7993 | 0.330 |
Why?
|
| Hormones | 3 | 2022 | 141 | 0.310 |
Why?
|
| Breast Neoplasms | 2 | 2021 | 2903 | 0.280 |
Why?
|
| Homeodomain Proteins | 3 | 2024 | 536 | 0.260 |
Why?
|
| Androgens | 3 | 2023 | 167 | 0.260 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 1464 | 0.250 |
Why?
|
| Neutropenia | 2 | 2023 | 215 | 0.250 |
Why?
|
| Nuclear Medicine | 1 | 2023 | 12 | 0.230 |
Why?
|
| CDC2 Protein Kinase | 1 | 2023 | 45 | 0.230 |
Why?
|
| Radium | 1 | 2023 | 7 | 0.230 |
Why?
|
| Adenocarcinoma | 2 | 2020 | 1169 | 0.220 |
Why?
|
| Capecitabine | 2 | 2024 | 96 | 0.220 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2023 | 122 | 0.220 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 621 | 0.210 |
Why?
|
| Frailty | 1 | 2023 | 58 | 0.210 |
Why?
|
| Dehydroepiandrosterone | 2 | 2020 | 51 | 0.210 |
Why?
|
| Urinary Bladder | 1 | 2024 | 246 | 0.210 |
Why?
|
| Disease-Free Survival | 4 | 2023 | 1204 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2017 | 1578 | 0.200 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 19 | 0.200 |
Why?
|
| Abiraterone Acetate | 2 | 2018 | 11 | 0.200 |
Why?
|
| Castration | 2 | 2012 | 41 | 0.200 |
Why?
|
| Health Expenditures | 1 | 2021 | 86 | 0.190 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2020 | 18 | 0.190 |
Why?
|
| Cell Cycle Proteins | 1 | 2023 | 388 | 0.190 |
Why?
|
| Glucocorticoids | 2 | 2024 | 352 | 0.190 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 1961 | 0.180 |
Why?
|
| Dietary Supplements | 1 | 2021 | 128 | 0.180 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2020 | 103 | 0.180 |
Why?
|
| Organic Chemicals | 1 | 2019 | 33 | 0.180 |
Why?
|
| Pain | 1 | 2022 | 391 | 0.180 |
Why?
|
| Boronic Acids | 1 | 2019 | 55 | 0.180 |
Why?
|
| Animals | 8 | 2024 | 26582 | 0.180 |
Why?
|
| Oxidoreductases | 1 | 2019 | 112 | 0.170 |
Why?
|
| United States | 6 | 2020 | 6672 | 0.170 |
Why?
|
| Pyridones | 1 | 2019 | 51 | 0.170 |
Why?
|
| Taxoids | 2 | 2016 | 129 | 0.170 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2020 | 166 | 0.170 |
Why?
|
| Aurora Kinase A | 1 | 2018 | 9 | 0.170 |
Why?
|
| Immunoconjugates | 1 | 2019 | 106 | 0.170 |
Why?
|
| Azepines | 1 | 2018 | 20 | 0.170 |
Why?
|
| Pyrrolidinones | 1 | 2018 | 16 | 0.170 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2018 | 28 | 0.170 |
Why?
|
| N-Myc Proto-Oncogene Protein | 1 | 2018 | 36 | 0.170 |
Why?
|
| Recurrence | 2 | 2019 | 1139 | 0.160 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2018 | 20 | 0.160 |
Why?
|
| Singapore | 1 | 2018 | 16 | 0.160 |
Why?
|
| Adult | 13 | 2021 | 25648 | 0.160 |
Why?
|
| Bone Neoplasms | 1 | 2020 | 322 | 0.160 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 318 | 0.160 |
Why?
|
| Quinolines | 1 | 2018 | 95 | 0.160 |
Why?
|
| Urologic Neoplasms | 1 | 2018 | 77 | 0.160 |
Why?
|
| Fasting | 1 | 2018 | 161 | 0.150 |
Why?
|
| Mice | 6 | 2024 | 11352 | 0.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 86 | 0.150 |
Why?
|
| Feasibility Studies | 2 | 2021 | 751 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2020 | 639 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2018 | 236 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 150 | 0.150 |
Why?
|
| Prostatectomy | 1 | 2020 | 471 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2018 | 199 | 0.140 |
Why?
|
| Quinolones | 1 | 2016 | 60 | 0.140 |
Why?
|
| Combined Modality Therapy | 4 | 2024 | 1686 | 0.140 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2016 | 458 | 0.140 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 301 | 0.140 |
Why?
|
| Tissue Array Analysis | 2 | 2018 | 124 | 0.140 |
Why?
|
| Benzodioxoles | 1 | 2015 | 16 | 0.140 |
Why?
|
| Female | 10 | 2021 | 44532 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2014 | 879 | 0.130 |
Why?
|
| Steroid Synthesis Inhibitors | 1 | 2014 | 1 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 426 | 0.130 |
Why?
|
| Maximum Tolerated Dose | 3 | 2019 | 270 | 0.130 |
Why?
|
| Metribolone | 1 | 2014 | 5 | 0.120 |
Why?
|
| Estrogen Receptor alpha | 1 | 2015 | 144 | 0.120 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2018 | 559 | 0.120 |
Why?
|
| Quinazolines | 1 | 2015 | 220 | 0.120 |
Why?
|
| Benzoates | 1 | 2014 | 44 | 0.120 |
Why?
|
| Prognosis | 3 | 2018 | 3679 | 0.120 |
Why?
|
| Proteins | 1 | 2019 | 777 | 0.120 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 311 | 0.120 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 1 | 2014 | 76 | 0.120 |
Why?
|
| Life Expectancy | 1 | 2014 | 86 | 0.120 |
Why?
|
| Immunoblotting | 1 | 2014 | 268 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2014 | 219 | 0.110 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2014 | 263 | 0.110 |
Why?
|
| Academic Medical Centers | 1 | 2015 | 379 | 0.110 |
Why?
|
| Hospitalization | 1 | 2018 | 849 | 0.110 |
Why?
|
| Flow Cytometry | 1 | 2014 | 679 | 0.110 |
Why?
|
| RNA Interference | 1 | 2014 | 369 | 0.110 |
Why?
|
| Immunotherapy | 1 | 2018 | 629 | 0.110 |
Why?
|
| Transcription Factors | 2 | 2018 | 1565 | 0.110 |
Why?
|
| Microscopy, Fluorescence | 1 | 2014 | 425 | 0.110 |
Why?
|
| Dexamethasone | 1 | 2014 | 326 | 0.110 |
Why?
|
| Transcription, Genetic | 1 | 2017 | 1135 | 0.110 |
Why?
|
| HEK293 Cells | 1 | 2014 | 615 | 0.100 |
Why?
|
| Indazoles | 3 | 2019 | 68 | 0.100 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2011 | 40 | 0.100 |
Why?
|
| G1 Phase | 1 | 2011 | 63 | 0.100 |
Why?
|
| Decision Making | 2 | 2014 | 642 | 0.100 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2011 | 157 | 0.090 |
Why?
|
| Survival Analysis | 1 | 2014 | 1538 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 1313 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 1863 | 0.090 |
Why?
|
| Early Detection of Cancer | 1 | 2014 | 394 | 0.090 |
Why?
|
| Tumor Burden | 1 | 2011 | 289 | 0.090 |
Why?
|
| Repressor Proteins | 1 | 2013 | 403 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 1673 | 0.090 |
Why?
|
| Administration, Cutaneous | 1 | 2009 | 58 | 0.090 |
Why?
|
| Muscle Strength | 1 | 2009 | 31 | 0.090 |
Why?
|
| Tissue Distribution | 2 | 2019 | 290 | 0.090 |
Why?
|
| Prostate | 3 | 2018 | 378 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2020 | 1823 | 0.080 |
Why?
|
| Research Design | 1 | 2012 | 594 | 0.080 |
Why?
|
| Nausea | 2 | 2019 | 175 | 0.080 |
Why?
|
| Geriatric Assessment | 2 | 2023 | 166 | 0.070 |
Why?
|
| Immunohistochemistry | 1 | 2011 | 1753 | 0.070 |
Why?
|
| Gene Expression Regulation | 1 | 2014 | 1920 | 0.070 |
Why?
|
| Rats | 1 | 2011 | 3990 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2024 | 8489 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2016 | 3362 | 0.060 |
Why?
|
| Precision Medicine | 2 | 2023 | 395 | 0.060 |
Why?
|
| Comorbidity | 2 | 2021 | 943 | 0.060 |
Why?
|
| Scandium | 1 | 2023 | 5 | 0.060 |
Why?
|
| Cohort Studies | 2 | 2021 | 2767 | 0.060 |
Why?
|
| Radioisotopes | 1 | 2023 | 45 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2021 | 2705 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2024 | 1981 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2024 | 393 | 0.060 |
Why?
|
| Cystectomy | 1 | 2024 | 102 | 0.060 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2023 | 72 | 0.050 |
Why?
|
| Early Termination of Clinical Trials | 2 | 2012 | 20 | 0.050 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 1939 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2022 | 28 | 0.050 |
Why?
|
| Febrile Neutropenia | 1 | 2022 | 14 | 0.050 |
Why?
|
| Neoplasm Invasiveness | 1 | 2024 | 552 | 0.050 |
Why?
|
| Aminopyridines | 1 | 2022 | 38 | 0.050 |
Why?
|
| Purines | 1 | 2022 | 91 | 0.050 |
Why?
|
| Thyrotoxicosis | 1 | 2001 | 18 | 0.050 |
Why?
|
| Tissue Extracts | 1 | 2021 | 24 | 0.050 |
Why?
|
| Interleukin-7 | 1 | 2021 | 41 | 0.050 |
Why?
|
| Cisplatin | 1 | 2024 | 612 | 0.050 |
Why?
|
| Keratins | 1 | 2021 | 63 | 0.050 |
Why?
|
| Leukocyte Common Antigens | 1 | 2021 | 46 | 0.050 |
Why?
|
| Neurosecretory Systems | 1 | 2021 | 35 | 0.050 |
Why?
|
| Time Factors | 2 | 2020 | 5210 | 0.050 |
Why?
|
| Cell Count | 1 | 2021 | 195 | 0.050 |
Why?
|
| Asymptomatic Diseases | 1 | 2021 | 41 | 0.050 |
Why?
|
| Prescription Drugs | 1 | 2021 | 36 | 0.050 |
Why?
|
| Thyroid Hormone Resistance Syndrome | 1 | 2001 | 116 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2021 | 248 | 0.050 |
Why?
|
| Cross-Over Studies | 1 | 2021 | 399 | 0.050 |
Why?
|
| RNA | 1 | 2024 | 560 | 0.050 |
Why?
|
| Neutrophils | 1 | 2021 | 307 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2021 | 464 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1014 | 0.040 |
Why?
|
| Steroids | 1 | 2020 | 177 | 0.040 |
Why?
|
| Chicago | 2 | 2015 | 1379 | 0.040 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2013 | 279 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2021 | 257 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 468 | 0.040 |
Why?
|
| Bradycardia | 1 | 2018 | 39 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2011 | 2262 | 0.040 |
Why?
|
| Lymphocyte Activation | 1 | 2021 | 728 | 0.040 |
Why?
|
| Pregnancy Complications | 1 | 2001 | 336 | 0.040 |
Why?
|
| Protein Isoforms | 1 | 2019 | 270 | 0.040 |
Why?
|
| Vomiting | 1 | 2019 | 193 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2019 | 325 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 916 | 0.040 |
Why?
|
| Kinetics | 1 | 2020 | 1513 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 860 | 0.040 |
Why?
|
| Risk Factors | 2 | 2020 | 5417 | 0.040 |
Why?
|
| Prevalence | 1 | 2021 | 1239 | 0.040 |
Why?
|
| Remission Induction | 1 | 2018 | 722 | 0.040 |
Why?
|
| Transcriptome | 1 | 2021 | 580 | 0.040 |
Why?
|
| Ketoconazole | 1 | 2014 | 25 | 0.030 |
Why?
|
| Nanog Homeobox Protein | 1 | 2014 | 7 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2016 | 684 | 0.030 |
Why?
|
| Retreatment | 1 | 2014 | 107 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 532 | 0.030 |
Why?
|
| Phenotype | 1 | 2021 | 2378 | 0.030 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2014 | 147 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2014 | 134 | 0.030 |
Why?
|
| Protein Binding | 1 | 2018 | 1456 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2019 | 1376 | 0.030 |
Why?
|
| Mortality | 1 | 2014 | 149 | 0.030 |
Why?
|
| Cause of Death | 1 | 2014 | 277 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2501 | 0.030 |
Why?
|
| Blotting, Western | 1 | 2014 | 782 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 2014 | 204 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2020 | 2261 | 0.030 |
Why?
|
| Embryonic Stem Cells | 1 | 2013 | 78 | 0.030 |
Why?
|
| Kallikreins | 1 | 2012 | 47 | 0.030 |
Why?
|
| United States Department of Defense | 1 | 2011 | 5 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 859 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2014 | 712 | 0.030 |
Why?
|
| Health Status | 1 | 2014 | 360 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 3640 | 0.030 |
Why?
|
| Contrast Media | 1 | 2016 | 1078 | 0.020 |
Why?
|
| Universities | 1 | 2011 | 135 | 0.020 |
Why?
|
| Fatigue | 1 | 2011 | 174 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 814 | 0.020 |
Why?
|
| Diarrhea | 1 | 2011 | 182 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2014 | 770 | 0.020 |
Why?
|
| Logistic Models | 1 | 2014 | 1186 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2011 | 227 | 0.020 |
Why?
|
| Smoking | 1 | 2014 | 609 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2012 | 351 | 0.020 |
Why?
|
| Mass Screening | 1 | 2014 | 618 | 0.020 |
Why?
|
| Age Factors | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Epithelial Cells | 1 | 2013 | 669 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 1621 | 0.020 |
Why?
|
| Patient Selection | 1 | 2012 | 685 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2008 | 125 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2012 | 508 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 5976 | 0.020 |
Why?
|
| Cell Death | 1 | 2008 | 256 | 0.020 |
Why?
|
| Adolescent | 1 | 2019 | 8981 | 0.020 |
Why?
|
| Cell Division | 1 | 2008 | 696 | 0.020 |
Why?
|
| Cell Cycle | 1 | 2008 | 502 | 0.020 |
Why?
|
| Homeostasis | 1 | 2008 | 409 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2011 | 1169 | 0.020 |
Why?
|
| Chorionic Gonadotropin | 1 | 2001 | 72 | 0.010 |
Why?
|
| Thyroid Function Tests | 1 | 2001 | 119 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 966 | 0.010 |
Why?
|
| Thyroid Hormones | 1 | 2001 | 321 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2001 | 695 | 0.010 |
Why?
|
| Pregnancy | 1 | 2001 | 2894 | 0.010 |
Why?
|